Pulsed field ablation was one of the biggest topics at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society. Medtronic, Johnson & Johnson MedTech, Boston Scientific, Abbott, Kardium and Field Medical all shared new data at the conference highlighting the safety and effectiveness of their advanced PFA technologies. 

Researchers have developed a deep learning model that can spot longitudinal changes in patients' brain imaging that could be indicative of cancer recurrence. 

Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways. 

Reviewing data from more than 6,000 patients, researchers found little evidence of the "obesity paradox" observed elsewhere. Underweight TAVR patients, however, may face some significant long-term risks.

The Millipede 088 was designed to treat large vessel occlusion stroke patients by “ingesting” the blood clot as opposed to dragging it through the patient’s blood vessels. 

India-based Meril Life Sciences has been manufacturing its Myval transcatheter heart valves for years, but the technology has not yet gained FDA approval. This latest head-to-head comparison included data from more than 1,000 TAVR patients.

Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.

“This is the perfect technique to identify high-risk patients who would benefit from intensive therapies,” imaging specialist Gudrun Feuchtner, MD, told Cardiovascular Business.